ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

In a report released on January 31, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target ...

(RTTNews) - Resmed Inc (RMD) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The company's earnings totaled $344.6 million, or $2.34 per share.

Sleep device giant ResMed expects to benefit from Donald Trump’s trade tariffs and tax cuts if competitors making rival products in China and Mexico are slapped with additional duties when they ...

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

We’ve updated this guide with new portable monitors we saw at CES 2025 that we plan to test soon. We’ve included more details in the What to look forward to section. January 2025 Rolling up to ...